Healthcare / Medical DevicesKOSDAQ
$5200.00
-260.00 (-4.91%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-2.9B · quality 45.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
22/100
D
Piotroski
8/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$81.1B
P/E
25.9x
↑EV/EBITDA
7.8x
↓ROE
4.1%
↑Gross Margin
47.4%
↓Debt/Equity
1.05
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-4.8%
FCF CAGR
—
FCF margin
8.3%
FCF / Net income
2.94x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $111.32B · net income $3.14B · FCF $9.23B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $111.32B | $111.32B | $79.84B | $145.88B | $129.00B |
| Net Income | $3.14B | $3.14B | $-60.43B | $-2.15B | $7.96B |
| EBITDA | $17.16B | $17.16B | $-42.37B | $7.62B | $20.54B |
| EPS | 201.00 | 201.00 | -3863.00 | -139.00 | 539.00 |
| Gross Margin | 47.4% | 47.4% | 45.1% | 48.7% | 48.5% |
| Operating Margin | -8.8% | -8.8% | -55.4% | 4.2% | 12.6% |
| Net Margin | 2.8% | 2.8% | -75.7% | -1.5% | 6.2% |
| Balance Sheet | |||||
| Debt/Equity | 1.05 | 1.05 | 1.16 | 0.68 | 0.71 |
| Current Ratio | 1.30 | 1.30 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $9.23B | $9.23B | $-2.89B | $-25.44B | $-40.94B |
| Returns | |||||
| ROE | 4.1% | 4.1% | -82.4% | -1.7% | 6.8% |
| Valuation | |||||
| P/E | 25.87 | 25.87 | — | — | 43.88 |
| EV/EBITDA | 7.78 | 7.78 | — | 57.54 | 20.17 |
| P/B | 1.06 | 1.06 | 1.42 | 2.92 | 3.00 |
| Growth & Yield | |||||
| Revenue Growth | 39.4% | 39.4% | -45.3% | 13.1% | — |
| EPS Growth | 105.2% | 105.2% | -2679.1% | -125.8% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
31.9%
EPS terminal req.
$461.41
Spread vs growth
73.3%
5Y implied EPS CAGR
22.7%
EPS terminal req.
$558.31
Spread vs growth
82.5%
10Y implied EPS CAGR
16.2%
EPS terminal req.
$899.16
Spread vs growth
89.0%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-37.5%
Start / end P/E
n/dx → n/dx
EPS bridge
-3863.00 → 201.00
Residual
-37.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.